Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
High Risk Superficial

Interventions: Biological: Bacillus Calmette-Guérin (BCG)

First Posted Date: 2014-11-02

Last Posted Date: 2023-02-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 80

Registration Number: NCT02281383

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 1 locations

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: external beam radiation therapy
Radiation: brachytherapy
Behavioral: questionnaires

First Posted Date: 2014-10-31

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT02280356

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 3 locations

Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery

Phase 1

Active, not recruiting

Conditions: Metastatic Spine Lesions

Interventions: Radiation: single-fraction radiation
Device: MRI and/or CT

First Posted Date: 2014-10-30

Last Posted Date: 2025-01-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT02278744

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients

Not Applicable

Completed

Conditions: Pediatric Pateints
Amnesic Properties of Propofol

Interventions: Other: memory test
Drug: Propofol

First Posted Date: 2014-10-29

Last Posted Date: 2018-01-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 69

Registration Number: NCT02278003

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Metastatic Prostate Cancer
Pain

Interventions: Drug: Radium-223

First Posted Date: 2014-10-29

Last Posted Date: 2023-04-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT02278055

Locations: 🇺🇸
New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity

Completed

Conditions: Chemotherapy Induced Cardiotoxicity in Breast Cancer Patients

Interventions: Device: cardiac MRI with DWI

First Posted Date: 2014-10-24

Last Posted Date: 2020-09-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT02274480

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1

Completed

Conditions: Ovarian Cancer
Endometrial Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Selinexor

First Posted Date: 2014-10-21

Last Posted Date: 2021-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT02269293

Locations: 🇺🇸
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Allogeneic Hematopoietic Stem Cell

Interventions: Other: No fecal microbiota transplantation (FMT), routine management
Biological: fecal microbiota transplantation (FMT)

First Posted Date: 2014-10-20

Last Posted Date: 2024-07-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT02269150

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1

Completed

Conditions: Advanced Gastrointestinal Stromal Tumor (GIST)

Interventions: Drug: BGJ398
Drug: Imatinib Mesylate

First Posted Date: 2014-10-06

Last Posted Date: 2020-03-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT02257541

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 4 locations

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Phase 2

Active, not recruiting

Conditions: Metastatic HER2-Positive Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2014-09-30

Last Posted Date: 2025-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT02252887

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy